7-alkylcarbonyl and 7-alkyloxycarbonyl prodrugs of theophylline

International Journal of Pharmaceutics

Volumn 205, Issue 1-2, 2000, Pages 53-63

  Sloan, Kenneth B ^a   Dellavecchia, Stephanie A ^a   Estes, Jessie V ^a   Roberts, William J ^a  

^a UNIVERSITY OF FLORIDA   (United States)

Author keywords

Alkylcarbonyl prodrugs; Alkyloxycarbonyl prodrugs; Diffusion cell experiments; Lipid solubility; Stability; Theophylline; Water solubility

Indexed keywords

7 ALKYLCARBONYL; 7 ALKYLOXYCARBONYL; MYRISTIC ACID ISOPROPYL ESTER; PRODRUG; THEOPHYLLINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; DIFFUSION; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG SYNTHESIS; FEMALE; HYDROLYSIS; LIPID SOLUBILITY; MOUSE; NONHUMAN; PHYSICAL CHEMISTRY; PRIORITY JOURNAL;

ANIMAL; HYDROGEN-ION CONCENTRATION; MICE; PHOSPHODIESTERASE INHIBITORS; PRODRUGS; SKIN ABSORPTION; SOLUBILITY; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.; THEOPHYLLINE;

EID: 0343714602     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0378-5173(00)00475-0     Document Type: Article

References (27)

1. Beall H.D., Sloan K.B. Transdermal delivery of 5-fluorouracil (5-FU) by 1-alkylcarbonyl-5-FU prodrugs. Int. J. Pharm. 129:1996;203-210.
2. Beall H.D., Getz J.J., Sloan K.B. The estimation of relative water solubility for prodrugs that are unstable in water. Int. J. Pharm. 93:1993;37-47.
3. Beall H., Prankerd R., Sloan K. Transdermal delivery of 5-fluorouracil (5-FU) through hairless mouse skin by 1-alkyloxycarbonyl-5-FU prodrugs; physicochemical characterization of prodrugs and correlations with transdermal delivery. Int. J. Pharm. 111:1994;223-233.
4. Berenbein B.A., Mikhailov G.S., Shumay N.T. Immediate results of psoriasis treatment with phosphodiesterase inhibitors. Vestn. Dermatol. Venerol. 5:1979;21-25.
5. Biltz H., Strufe K. 7-Acyltheophylline und ihr Abbau. Justus Liebigs Ann. Chem. 404:1914;171-180.
6. Bodor N., Sloan K.B., Kno Y.-N., Higuchi T. Controlled delivery of theophylline: chemistry of 7-acyl- and 7,7′-acylditheophylline derivatives. J. Pharm. Sci. 67:1978;1045-1050.
7. Bourne H.R., Lichtenstein L.M., Melmon K.L., Henney C.S., Weinstein Y., Shearer G.M. Modulation of inflammation and immunity by cyclic AMP. Science. 184:1974;19-28.
8. Fedors R.F. A method for estimating both the solubility parameters and molar volumes of liquids. Polym. Eng. Sci. 14:1974;147-154.
9. Giani M., Molteni L. Theophylline derivatives of pharmacological interest. Farmaco Ed. Sci. 12:1957;1016-1024.
10. Higuchi T., Lee H.K., Pitman I.H. Analysis of possible accelerating influence of irreversible chemical reactions on dissolution rates of reactive solids. Dissolution behavior of 7-acetyltheophylline. Farm. Aikak. 80:1971;55-90.
11. Iancu L., Shneur A., Cohen H. Trials with xanthine derivatives in systemic treatment of psoriasis. Dermatologica. 159:1979;55-61.
12. 9-acylpurines with acylated sugars. J. Chem. Soc. Jpn. 37:1964;1389-1390.
13. Kerr D., Roberts W., Tebbett I., Sloan K.B. 7-Alkylcarbonyloxymethyl prodrugs of theophylline: topical delivery of theophylline. Int. J. Pharm. 167:1998;37-48.
14. Lee H.K., Lambert H., Stella V.J., Wang D., Higuchi T. Hydrolysis and dissolution behavior of a prolonged-release prodrug of theophylline: 7,7′-succinylditheophylline. J. Pharm. Sci. 68:1979;288-295.
15. Martin A., Wu P.L., Velasquez T. Extended Hildebrand solubility approach: sulfonamides in binary and ternary solvents. J. Pharm. Sci. 74:1985;277-282.
16. Roberts W.J., Sloan K.B. Correlation of aqueous and lipid solubilities with flux for prodrugs of 5-fluorouracil, theophylline and 6-mercaptopurine: a Potts-Guy approach. J. Pharm. Sci. 88:1999;515-522.
17. Sherertz E.F., Sloan K.B., McTiernan R.G. Effect of skin pretreatment with vehicle alone or drug in vehicle on flux of a subsequently applied drug: results of hairless mouse skin and diffusion cell studies. J. Invest. Dermatol. 89:1987;249-252.
18. Sloan K.B. Functional group considerations in the development of prodrug approaches to solving topical delivery problems. Sloan K.B. Prodrugs: Topical and Ocular Drug Delivery. 1992;17-116 Marcel Dekker, New York, NY.
19. Sloan K.B., Koch S.A.M., Siver K.G., Flowers F.P. The use of solubility parameters of drug and vehicle to predict flux. J. Invest. Dermatol. 87:1986;244-252.
20. Sloan K.B., Beall H.D., Weimar W.R., Villaneuva R. The effect of receptor phase composition on the permeability of hairless mouse skin in diffusion cell experiments. Int. J. Pharm. 73:1991;97-104.
21. Sloan K.B., Getz J.J., Beall H.D., Prankerd R.J. Transdermal delivery of 5-fluorouracil (5-FU) through hairless mouse skin by 1-alkylaminocarbonyl-5-FU prodrugs: physicochemical characterization of prodrugs and correlations with transdermal delivery. Int. J. Pharm. 93:1993;27-36.
22. Sloan K.B., Beall H.D., Taylor H.E., Getz J.J., Villaneuva R., Nipper R., Smith K. Transdermal delivery of theophylline from alcohol vehicles. Int. J. Pharm. 171:1998;185-193.
23. Taylor H.E., Sloan K.B. 1-Alkylcarbonyloxymethyl prodrugs of 5-fluorouracil (5-FU): synthesis, physicochemical properties and topical delivery of 5-FU. J. Pharm. Sci. 87:1998;15-20.
24. Vieth H., Leube E. Uber die diuretische Wirkung einiger derivate des theobromins. Biochem. Z. 163:1925;13-26.
25. Voorhees J.J., Duell E.A. Psoriasis as a possible defect of the adenyl cyclase-cyclic AMP cascade. Arch. Dermatol. 104:1971;352-358.
26. 6-acyloxymethyl-6-mercaptopurine prodrugs. J. Pharm. Sci. 77:1986;210-215.
27. Yalkowsky S.H. Solubility and melting point considerations in drug design. Roche E.B. Design of Biopharmaceutical Properties through Prodrugs and Analogues. 1977;392-408 American Pharmaceutical Association Academy of Pharmaceutical Sciences, Washington, DC.